Phase III BELINDA Trial of Tisagenlecleucel vs Standard of Care as Second-line Treatment for R/R Aggressive B-Cell Non-Hodgkin Lymphoma

Source: 2021 American Society of Hematology Annual Meeting*
Download Slideset
December 11-14, 2021; Atlanta, Georgia
In the phase III BELINDA trial, tisagenlecleucel as second-line therapy in patients with R/R aggressive B-cell NHL had no significant impact on event-free survival vs standard of care.
Format: Microsoft PowerPoint (.ppt)
File Size: 176 KB
Released: December 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings